Curemark Appoints Dr. William R. McIntyre as Senior Vice President

Curemark announced today the key addition of Dr. William R. McIntyre to the team as the Senior Vice President of Global Regulatory Affairs, effective immediately.

Previously, Dr. McIntyre served as Senior Vice President of Regulatory Affairs for Endo Par and oversaw the approval of 4 NDAs for Pfizer as Associate Director of Regulatory Affairs. Dr. McIntyre earned his PhD with Distinction at New York University, was awarded a post-doctoral Research Fellowship from the National Institutes of Health and served a post-doctoral residency at NYU Medical Center’s Department of Molecular Endocrinology.

Curemark CEO Dr. Joan Fallon stated, “I’m excited that Dr. McIntyre is onboard as he brings a wealth of regulatory experience to our BLA filing process. He is the right person to lead our regulatory team into the future.”

Dr. McIntyre commented, “I’m truly grateful to Dr. Fallon for the opportunity to be a part of Curemark. Throughout my career in pharma, I’ve always looked towards situations where unmet medical needs are addressed. Curemark’s platform technology seeks to solve problems where there is great need and little or no treatment.”

ABOUT CUREMARK

Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of autism, schizophrenia and Parkinson’s disease, ADHD and addiction. For additional information, please visit our website at http://www.curemark.com or follow @Curemark on Twitter.